# Rani Therapeutics Holdings, Inc.: financial statements, quarterly

RANI · Nasdaq · CIK 1856725 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rani.md) · [Financials](/companies/rani/financials.md) · [Filings](/companies/rani/filings.md) · [Insiders](/companies/rani/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rani/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0000950170-25-070382.md) | [0.0](/filings/0000950170-25-105045.md) | [0.0](/filings/0001193125-25-269774.md) | [1.0 d](/filings/0001193125-26-126417.md) | [0.2](/filings/0001193125-26-226703.md) | [0.0](/filings/0001193125-26-349245.md) | [0.0](/filings/0001193125-25-269774.md) | [1.5 d](/filings/0001193125-26-126417.md) | [1.7](/filings/0001193125-26-226703.md) | [1.7](/filings/0001193125-26-349245.md) |
| Research and development | $m | [11.2](/filings/0000950170-24-126763.md) | [7.6 d](/filings/0000950170-25-047740.md) | [7.6](/filings/0000950170-25-070382.md) | [6.1](/filings/0000950170-25-105045.md) | [6.2](/filings/0001193125-25-269774.md) | [6.8 d](/filings/0001193125-26-126417.md) | [6.6](/filings/0001193125-26-226703.md) | [5.5](/filings/0001193125-26-349245.md) | [3.2](/filings/0001193125-25-269774.md) | [4.9 d](/filings/0001193125-26-126417.md) | [5.2](/filings/0001193125-26-226703.md) | [5.0](/filings/0001193125-26-349245.md) |
| Operating income | $m | [(17.9)](/filings/0000950170-24-126763.md) | [(13.4) d](/filings/0000950170-25-047740.md) | [(14.0)](/filings/0000950170-25-070382.md) | [(12.5)](/filings/0000950170-25-105045.md) | [(11.8)](/filings/0001193125-25-269774.md) | [(15.0) d](/filings/0001193125-26-126417.md) | [(12.0)](/filings/0001193125-26-226703.md) | [(10.5)](/filings/0001193125-26-349245.md) | [(7.3)](/filings/0001193125-25-269774.md) | [(8.5) d](/filings/0001193125-26-126417.md) | [(8.3)](/filings/0001193125-26-226703.md) | [(8.8)](/filings/0001193125-26-349245.md) |
| Interest expense | $m | [1.3](/filings/0000950170-24-126763.md) | [1.3 d](/filings/0000950170-25-047740.md) | [1.3](/filings/0000950170-25-070382.md) | [1.3](/filings/0000950170-25-105045.md) | [1.3](/filings/0001193125-25-269774.md) | [1.1 d](/filings/0001193125-26-126417.md) | [0.9](/filings/0001193125-26-226703.md) | [0.9](/filings/0001193125-26-349245.md) | [0.7](/filings/0001193125-25-269774.md) | [0.3 d](/filings/0001193125-26-126417.md) | [0.1](/filings/0001193125-26-226703.md) | [0.0](/filings/0001193125-26-349245.md) |
| Income tax | $m | [0.0](/filings/0000950170-23-061137.md) | [0.0 d](/filings/0000950170-25-047740.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(9.2)](/filings/0000950170-24-126763.md) | [(7.1) d](/filings/0000950170-25-047740.md) | [(7.5)](/filings/0000950170-25-070382.md) | [(6.8)](/filings/0000950170-25-105045.md) | [(6.8)](/filings/0001193125-25-269774.md) | [(8.9) d](/filings/0001193125-26-126417.md) | [(7.3)](/filings/0001193125-26-226703.md) | [(6.7)](/filings/0001193125-26-349245.md) | [(5.4)](/filings/0001193125-25-269774.md) | [(10.3) d](/filings/0001193125-26-126417.md) | [(7.0)](/filings/0001193125-26-226703.md) | [(7.4)](/filings/0001193125-26-349245.md) |
| Diluted EPS | $ per share | [(0.36)](/filings/0000950170-24-126763.md) | not reported | [(0.29)](/filings/0000950170-25-070382.md) | [(0.26)](/filings/0000950170-25-105045.md) | [(0.24)](/filings/0001193125-25-269774.md) | not reported | [(0.22)](/filings/0001193125-26-226703.md) | [(0.18)](/filings/0001193125-26-349245.md) | [(0.12)](/filings/0001193125-25-269774.md) | not reported | [(0.04)](/filings/0001193125-26-226703.md) | [(0.04)](/filings/0001193125-26-349245.md) |
| Basic EPS | $ per share | [(0.36)](/filings/0000950170-24-126763.md) | not reported | [(0.29)](/filings/0000950170-25-070382.md) | [(0.26)](/filings/0000950170-25-105045.md) | [(0.24)](/filings/0001193125-25-269774.md) | not reported | [(0.22)](/filings/0001193125-26-226703.md) | [(0.18)](/filings/0001193125-26-349245.md) | [(0.12)](/filings/0001193125-25-269774.md) | not reported | [(0.04)](/filings/0001193125-26-226703.md) | [(0.04)](/filings/0001193125-26-349245.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.0](/filings/0000950170-24-126763.md) | [5.9](/filings/0000950170-25-047740.md) | [6.9](/filings/0000950170-25-070382.md) | [4.5](/filings/0000950170-25-105045.md) | [4.3](/filings/0001193125-25-269774.md) | [3.8](/filings/0001193125-26-126417.md) | [10.1](/filings/0001193125-26-226703.md) | [10.2](/filings/0001193125-26-349245.md) | [4.1](/filings/0001193125-25-269774.md) | [18.6](/filings/0001193125-26-349245.md) | [9.6](/filings/0001193125-26-226703.md) | [4.9](/filings/0001193125-26-349245.md) |
| Current assets | $m | [63.2](/filings/0000950170-23-061137.md) | [50.8](/filings/0000950170-25-047740.md) | [41.4](/filings/0000950170-24-053548.md) | [32.0](/filings/0000950170-24-091793.md) | [32.4](/filings/0000950170-24-126763.md) | [29.7](/filings/0001193125-26-126417.md) | [17.8](/filings/0000950170-25-070382.md) | [11.1](/filings/0000950170-25-105045.md) | [5.0](/filings/0001193125-25-269774.md) | [53.3](/filings/0001193125-26-349245.md) | [47.1](/filings/0001193125-26-226703.md) | [56.5](/filings/0001193125-26-349245.md) |
| Total assets | $m | [70.4](/filings/0000950170-23-061137.md) | [57.9](/filings/0000950170-25-047740.md) | [53.5](/filings/0000950170-24-053548.md) | [43.7](/filings/0000950170-24-091793.md) | [43.5](/filings/0000950170-24-126763.md) | [36.6](/filings/0001193125-26-126417.md) | [24.1](/filings/0000950170-25-070382.md) | [16.9](/filings/0000950170-25-105045.md) | [10.1](/filings/0001193125-25-269774.md) | [58.6](/filings/0001193125-26-349245.md) | [51.9](/filings/0001193125-26-226703.md) | [60.8](/filings/0001193125-26-349245.md) |
| Current liabilities | $m | [7.3](/filings/0000950170-23-061137.md) | [8.0](/filings/0000950170-25-047740.md) | [13.4](/filings/0000950170-24-053548.md) | [16.6](/filings/0000950170-24-091793.md) | [20.2](/filings/0000950170-24-126763.md) | [19.9](/filings/0001193125-26-126417.md) | [20.1](/filings/0000950170-25-070382.md) | [20.6](/filings/0000950170-25-105045.md) | [19.1](/filings/0001193125-25-269774.md) | [12.7](/filings/0001193125-26-349245.md) | [13.9](/filings/0001193125-26-226703.md) | [10.6](/filings/0001193125-26-349245.md) |
| Total liabilities | $m | [35.6](/filings/0000950170-23-061137.md) | [32.5](/filings/0000950170-25-047740.md) | [39.0](/filings/0000950170-24-053548.md) | [38.2](/filings/0000950170-24-091793.md) | [37.8](/filings/0000950170-24-126763.md) | [33.1](/filings/0001193125-26-126417.md) | [29.5](/filings/0000950170-25-070382.md) | [26.1](/filings/0000950170-25-105045.md) | [22.1](/filings/0001193125-25-269774.md) | [17.1](/filings/0001193125-26-349245.md) | [16.3](/filings/0001193125-26-226703.md) | [12.9](/filings/0001193125-26-349245.md) |
| Long-term debt | $m | [28.1](/filings/0000950170-23-061137.md) | [24.5](/filings/0000950170-25-047740.md) | [20.9](/filings/0000950170-24-053548.md) | [17.2](/filings/0000950170-24-091793.md) | [13.5](/filings/0000950170-24-126763.md) | [9.6](/filings/0001193125-26-126417.md) | [5.9](/filings/0000950170-25-070382.md) | [2.2](/filings/0000950170-25-105045.md) | [0.0](/filings/0001193125-25-269774.md) | [0.0](/filings/0001193125-26-126417.md) | not reported | not reported |
| Current portion of debt | $m | [1.2](/filings/0000950170-23-061137.md) | [4.9](/filings/0000950170-25-047740.md) | [8.6](/filings/0000950170-24-053548.md) | [12.3](/filings/0000950170-24-091793.md) | [14.8](/filings/0000950170-24-126763.md) | [15.0](/filings/0001193125-26-126417.md) | [15.0](/filings/0000950170-25-070382.md) | [15.0](/filings/0000950170-25-105045.md) | [13.5](/filings/0001193125-25-269774.md) | [0.0](/filings/0001193125-26-126417.md) | not reported | not reported |
| Shareholders' equity | $m | [17.6](/filings/0000950170-23-061137.md) | [12.9](/filings/0000950170-25-047740.md) | [7.4](/filings/0000950170-24-053548.md) | [2.8](/filings/0000950170-24-091793.md) | [3.1](/filings/0000950170-24-126763.md) | [2.0](/filings/0001193125-26-126417.md) | [(3.1)](/filings/0000950170-25-070382.md) | [(5.6)](/filings/0000950170-25-105045.md) | [(7.9)](/filings/0001193125-25-269774.md) | [33.0](/filings/0001193125-26-349245.md) | [28.4](/filings/0001193125-26-226703.md) | [39.2](/filings/0001193125-26-349245.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(14.3) d](/filings/0000950170-24-126763.md) | [(12.5) d](/filings/0000950170-25-047740.md) | [(9.4)](/filings/0000950170-25-070382.md) | [(9.0) d](/filings/0000950170-25-105045.md) | [(8.4) d](/filings/0001193125-25-269774.md) | [(8.7) d](/filings/0001193125-26-126417.md) | [(8.1)](/filings/0001193125-26-226703.md) | [(5.8) d](/filings/0001193125-26-349245.md) | [(5.1) d](/filings/0001193125-25-269774.md) | [0.3 d](/filings/0001193125-26-126417.md) | [(6.5)](/filings/0001193125-26-226703.md) | [(9.0) d](/filings/0001193125-26-349245.md) |
| Capital expenditure | $m | [0.5 d](/filings/0000950170-24-126763.md) | [0.2 d](/filings/0000950170-25-047740.md) | [0.0](/filings/0000950170-25-070382.md) | [0.1 d](/filings/0000950170-25-105045.md) | [0.1 d](/filings/0001193125-25-269774.md) | [0.0 d](/filings/0001193125-26-126417.md) | [0.1](/filings/0001193125-26-226703.md) | [0.0 d](/filings/0001193125-26-349245.md) | [0.0 d](/filings/0001193125-25-269774.md) | [0.0 d](/filings/0001193125-26-126417.md) | [0.0](/filings/0001193125-26-226703.md) | [0.0 d](/filings/0001193125-26-349245.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [24.5](/filings/0000950170-23-061137.md) | [25.2](/filings/0000950170-24-053548.md) | [25.3](/filings/0000950170-24-091793.md) | [25.6](/filings/0000950170-24-126763.md) | [26.0](/filings/0000950170-25-070382.md) | [26.3](/filings/0000950170-25-105045.md) | [28.8](/filings/0001193125-25-269774.md) | [33.4](/filings/0001193125-26-226703.md) | [36.5](/filings/0001193125-26-349245.md) | [46.4](/filings/0001193125-25-269774.md) | [180](/filings/0001193125-26-226703.md) | [187](/filings/0001193125-26-349245.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.